抗Human CCL22/MDC抗体(Anti-Human CCL22/MDC antibody)

• 価格
• Product Details
• Applications and Data
• Data Examples
• References
• Related Research Areas
• Related Product & Information
• Citations

価格

目次に戻る

Product Details

Species Reactivity	Human
Label	Unconjugated
Immunogen	E. coli-derived recombinant human CCL22/MDCGly25-Gln93Accession # O00626.1
Source	Monoclonal Mouse IgG2B Clone # 57226
Purification	Protein A or G purified from ascites
Specificity	Detects human CCL22/MDC in ELISAs and Western blots. In ELISAs, no cross-reactivity with recombinant mouse CCL17, recombinant human (rh) CCL17, or rhCCL21 is observed.

目次に戻る

Applications and Data

	Recommended Concentration	Sample
Western Blot	1 µg/mL	Recombinant Human CCL22/MDC (Catalog # 336-MD)
Human CCL22/MDC Sandwich Immunoassay	Reagent
ELISA Capture (Matched Antibody Pair)	2-8 µg/mL	Human CCL22/MDC Antibody (Catalog #MAB336 )
ELISA Detection (Matched Antibody Pair)	0.1-0.4 µg/mL	Human CCL22/MDC Biotinylated Antibody (Catalog #BAF336 )
ELISA Standard		Recombinant Human CCL22/MDC Protein (Catalog #336-MD )
Neutralization	Measured by its ability to neutralize CCL22/MDC-induced chemotaxis in the BaF3 mouse pro‑B cell line transfected with human CCR4. The Neutralization Dose (ND50) is typically 0.6-3.0 µg/mL in the presence of 10 ng/mL Recombinant Human CCL22/MDC.
Please Note: Optimal dilutions should be determined by each laboratory for each application.General Protocolsare available in the Technical Information section on our website.

目次に戻る

Data Examples

Neutralization	click image to view larger	Chemotaxis Induced by CCL22/MDC and Neutralization by Human CCL22/MDC Antibody.Recombinant Human CCL22/MDC (Catalog # 336-MD) chemoattracts the BaF3 mouse pro‑B cell line transfected with human CCR4 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Human CCL22/MDC (10 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human CCL22/MDC Monoclonal Antibody (Catalog # MAB336). The ND50 is typically 0.6-3.0 µg/mL.
Reconstitution	Reconstitute at 0.5 mg/mL in sterile PBS.	Reconstitution Buffer Available
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: CCL22/MDC	CCL22, also named stimulated T cell chemotactic protein (STCP-1) and MDC, is a CC chemokine initially isolated from clones of monocyte-derived macrophages. Human CCL22 cDNA encodes a precursor protein of 93 amino acid residues with a 24 amino acid residue predicted signal peptide that is cleaved to yield a 69 amino acid residue mature 8 kDa protein. At the amino acid sequence level, CCL22 shows less than 35% identity to other CC chemokine family members. Human CCL22 is expressed in dendritic cells, macrophages and activated monocytes. In addition, CCL22 expression is also detected in the tissues of thymus, lymph node and appendix. The gene for human CCL22 has been mapped to chromosome 16 rather than chromosome 17 where the genes for many human CC chemokines are clustered. Recombinant or chemically synthesized mature CCL22 has been shown to induce chemotaxis or Ca2+ mobilization in dendritic cells, IL-2 activated NK cells, and activated T lymphocytes. A CD8+ T lymphocyte-derived secreted soluble activity that suppresses infection by primary non-syncytium-inducing and syncytium-inducing HIV-1 isolates and the T cell line-adapted isolate HIV-1IIIB, has been identified as CCL22. Based on amino-terminal sequence analysis, the major CD8+ T lymphocyte-derived CCL22 protein yielded an amino-terminal sequence of YGANM, which is two amino acid residues shorter than the predicted mature CCL22. The difference in potency between the two mature CCL22 isoforms has not been determined.

目次に戻る

References

Godiska, R. et al. (1997) J. Exp. Med. 185:1595.
Chang, M-S. et al. (1997) J. Biol. Chem. 272:25229.
Pal, R. et al. (1997) Science 278:5338.
Entrez Gene IDs:	6367 (Human); 20299 (Mouse)
Alternate Names:	A-152E5.1; ABCD-1; CC chemokine STCP-1; C-C motif chemokine 22; CCL22; chemokine (C-C motif) ligand 22; DC/B-CK; Macrophage-derived chemokine; MDC; MDCStimulated T-cell chemotactic protein 1; MGC34554; SCYA22MDC(1-69); small inducible cytokine A22; small inducible cytokine subfamily A (Cys-Cys), member 22; Small-inducible cytokine A22; STCP-1; stimulated T cell chemotactic protein 1

目次に戻る

Related Research Areas

CC Chemokines and Receptors

Chemokines and Receptors

Chemokines and Receptors in Allergy and Asthma

Macrophage Activation Markers

Molecules Secreted by VSMC

Regulatory T Cells (Tregs)

Th9 Cells

Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver. Authors: Oo YH, Weston CJ, Lalor PF, Curbishley SM, Withers DR, Reynolds GM, Shetty S, Harki J, Shaw JC, Eksteen B, Hubscher SG, Walker LS, Adams DH J. Immunol., 2010;184(6):2886-98. Species: Human Sample Type: Whole Tissue Application: IHC Paraffin-embedded

Neutralization

Chemotaxis Induced by CCL22/MDC and Neutralization by Human CCL22/MDC Antibody. Recombinant Human CCL22/MDC (Catalog # 336-MD) chemoattracts the BaF3 mouse pro‑B cell line transfected with human CCR4 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Human CCL22/MDC (10 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human CCL22/MDC Monoclonal Antibody (Catalog # MAB336). The ND50 is typically 0.6-3.0 µg/mL.

目次に戻る

Related Product & Information

Entrez Gene IDs	6367 (Human); 20299 (Mouse)
Background	CCL22/MDC
background_content	Background: CCL22/MDC CCL22, also named stimulated T cell chemotactic protein (STCP-1) and MDC, is a CC chemokine initially isolated from clones of monocyte-derived macrophages. Human CCL22 cDNA encodes a precursor protein of 93 amino acid residues with a 24 amino acid residue predicted signal peptide that is cleaved to yield a 69 amino acid residue mature 8 kDa protein. At the amino acid sequence level, CCL22 shows less than 35% identity to other CC chemokine family members. Human CCL22 is expressed in dendritic cells, macrophages and activated monocytes. In addition, CCL22 expression is also detected in the tissues of thymus, lymph node and appendix. The gene for human CCL22 has been mapped to chromosome 16 rather than chromosome 17 where the genes for many human CC chemokines are clustered. Recombinant or chemically synthesized mature CCL22 has been shown to induce chemotaxis or Ca2+ mobilization in dendritic cells, IL-2 activated NK cells, and activated T lymphocytes. A CD8+ T lymphocyte-derived secreted soluble activity that suppresses infection by primary non-syncytium-inducing and syncytium-inducing HIV-1 isolates and the T cell line-adapted isolate HIV-1IIIB, has been identified as CCL22. Based on amino-terminal sequence analysis, the major CD8+ T lymphocyte-derived CCL22 protein yielded an amino-terminal sequence of YGANM, which is two amino acid residues shorter than the predicted mature CCL22. The difference in potency between the two mature CCL22 isoforms has not been determined.

目次に戻る

Citations

1. Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver.
   Authors: Oo YH, Weston CJ, Lalor PF, Curbishley SM, Withers DR, Reynolds GM, Shetty S, Harki J, Shaw JC, Eksteen B, Hubscher SG, Walker LS, Adams DH
   J. Immunol., 2010;184(6):2886-98.
   Species: Human
   Sample Type: Whole Tissue
   Application: IHC Paraffin-embedded


2. CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer.
   Authors: Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H, Fujii H
   Int. J. Cancer, 2008;122(10):2286-93.
   Species: Human
   Sample Type: Whole Cells
   Application: Flow


3. Specific recruitment of regulatory T cells into the CSF in lymphomatous and carcinomatous meningitis.
   Authors: Haas J, Schopp L, Storch-Hagenlocher B, Fritzsching B, Jacobi C, Milkova L, Fritz B, Schwarz A, Suri-Payer E, Hensel M, Wildemann B
   Blood, 2007;111(2):761-6.
   Species: Human
   Sample Type: Whole Cells
   Application: Neut


4. Generation of Th1 and Th2 chemokines by human eosinophils: evidence for a critical role of TNF-alpha.
   Authors: Liu LY, Bates ME, Jarjour NN, Busse WW, Bertics PJ, Kelly EA
   J. Immunol., 2007;179(7):4840-8.
   Species: Human
   Sample Type: Cell Culture Supernates
   Application: ELISA Development


5. Enhanced generation of helper T type 1 and 2 chemokines in allergen-induced asthma.
   Authors: Liu L, Jarjour NN, Busse WW, Kelly EA
   Am. J. Respir. Crit. Care Med., 2004;169(10):1118-24.
   Species: Human
   Sample Type: BALF
   Application: ELISA Development


6. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
   Authors: Curiel, Tyler J, Coukos, George, Zou, Linhua, Alvarez, Xavier, Cheng, Pui, Mottram, Peter, Evdemon-Hogan, Melina, Conejo-Garcia, Jose R, Zhang, Lin, Burow, Matthew, Zhu, Yun, Wei, Shuang, Kryczek, Ilona, Daniel, Ben, Gordon, Alan, Myers, Leann, Lackner, Andrew, Disis, Mary L, Knutson, Keith L, Chen, Lieping, Zou, Weiping
   Nat Med, 2004;10(9):942-9.
   Species: Human
   Sample Type: Whole Cells
   Application: Neut


7. CCR4 blockade does not inhibit allergic airways inflammation.
   Authors: Conroy DM, Jopling LA, Lloyd CM, Hodge MR, Andrew DP, Williams TJ, Pease JE, Sabroe I
   J. Leukoc. Biol., 2003;74(4):558-63.
   Species: Guinea Pig
   Sample Type: BALF
   Application: ELISA Development

目次に戻る